Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. Offered by National Institutes of Health; awards $500K; applications due August 13, 2026.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- $500K
- Deadline
- August 13, 2026
- Geography
- national
- Categories
- Healthcare, Research
- Status
- Open
About This Grant
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.
Full requirements and application instructions: official listing.
Similar Open Grants
Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)
National Institutes of Health
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
National Institutes of Health
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
National Institutes of Health
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
National Institutes of Health
DoW Multiple Sclerosis Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
DoW Multiple Sclerosis Early Investigator Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Multiple Sclerosis Exploration-Hypothesis Development Award
Defense Health Agency Contracting Activity - DHACA
DoW Multiple Sclerosis Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA